HPV Update: Vaccination, Screening, and Associated Disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27184752.
- Also identified by DOI 10.1007/s11606-016-3725-z and PMC identifier 5071275.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Human papillomavirus (HPV) infection is the causative agent in cervical cancer, and is associated with numerous other genital cancers, including vulvar, vaginal, and anal cancer. Primary prevention with HPV vaccination is safe and efficacious, and a recently approved HPV vaccine will provide even more extensive protection against several oncogenic HPV strains. Screening strategies for HPV are rapidly evolving, reflecting the essential role that HPV infection plays in cervical cancer. This article highlights new evidence regarding the efficacy of the recently approved 9-valent HPV (9vHPV) vaccine and the use of primary high-risk HPV testing in cervical cancer screening. We consider the utility of urinary HPV testing in routine clinical practice and review current guidelines regarding anal HPV screening.
Medical subject headings
- Early Detection of Cancer
- Papillomavirus Infections
- Papillomavirus Vaccines
- Uterine Cervical Neoplasms
- Vaccination